1. Home
  2. GRF vs TELA Comparison

GRF vs TELA Comparison

Compare GRF & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

HOLD

Current Price

$10.82

Market Cap

43.9M

Sector

Finance

ML Signal

HOLD

Logo TELA Bio Inc.

TELA

TELA Bio Inc.

HOLD

Current Price

$0.78

Market Cap

36.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRF
TELA
Founded
1989
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.9M
36.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GRF
TELA
Price
$10.82
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.31
AVG Volume (30 Days)
3.0K
330.9K
Earning Date
01-01-0001
03-19-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
N/A
EPS
1.16
N/A
Revenue
N/A
$77,055,000.00
Revenue This Year
N/A
$18.41
Revenue Next Year
N/A
$15.20
P/E Ratio
$8.15
N/A
Revenue Growth
N/A
12.24
52 Week Low
$7.93
$0.68
52 Week High
$10.19
$2.96

Technical Indicators

Market Signals
Indicator
GRF
TELA
Relative Strength Index (RSI) 48.65 36.78
Support Level $10.75 $0.76
Resistance Level $11.09 $0.86
Average True Range (ATR) 0.16 0.11
MACD -0.00 -0.00
Stochastic Oscillator 45.60 27.30

Price Performance

Historical Comparison
GRF
TELA

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Share on Social Networks: